Medical cannabis as an Adjunctive Therapy in Schizophrenia
According to a study published in 2017 by the American Journal of Psychiatry, researchers have come to a conclusion that CBD can have a positive effect in patients with schizophrenia.
Studies about medical cannabis efficacy for Schizophrenia
The aim of this study was to investigate the safety and efficacy of CBD as an accompanying therapy for schizophrenia. In a randomized (1:1 ratio) and double-blinded study, patients received either CBD (1000mg/day; N=43) or a placebo (N=45) as additional therapy to their existing antipsychotic medication for 6 weeks. Participants were assessed for effects of CBD before and after the treatment using the positive and negative Syndrom scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S).According to the study, the CBD group, compared to the placebo group, showed improvements in cognitive performance, functional range, and overall clinical impression of the patient.
These results suggest that CBD may be a possible alternative in the treatment of schizophrenia.
